Modafinil as a catecholaminergic agent: Empirical evidence and unanswered questions

Frontiers in Neurology

Volumn 4 OCT, Issue , 2013, Pages

  Wisor, Jonathan ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Addiction; Amphetamines; Cocaine; Dopamine transporter; Modafinil; Monoamines; Sleep homeostasis; Wake promoting therapeutics

Indexed keywords

AMPHETAMINE; ARMODAFINIL; COCAINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; MODAFINIL;

BINDING AFFINITY; BRAIN REGION; CATALEPSY; CATAPLEXY; CONCENTRATION RESPONSE; DISCRIMINATIVE STIMULUS; DOPAMINE UPTAKE; DRUG ABUSE; DRUG BRAIN LEVEL; DRUG DEPENDENCE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; IC 50; LIGAND BINDING; NEUROTRANSMISSION; NONHUMAN; PHARMACOLOGICAL BLOCKING; REVIEW; SLEEP WAKING CYCLE; SOMNOLENCE; WAKEFULNESS;

EID: 84885368200     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00139     Document Type: Review

References (105)

1. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry (1988) 12(5):695-700. doi:10.1016/0278-5846(88)90014-0.
2. Provigil A® (Modafinil) Tablets [C-IV] [Package Insert]. Frazer, PA: Cephalon, Inc. (2010).
3. Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol (1999) 39:30-40. doi:10.1177/00912709922007534.
4. Nuvigil A® (Armodafinil) Tablets [C-IV] [Package Insert]. Frazer, PA: Cephalon, Inc. (2010).
5. Ballas CA, Kim D, Baldassano CF, Hoeh N. Modafinil: past, present and future. Expert Rev Neurother (2002) 2(4):449-57. doi:10.1586/14737175.2.4.449.
6. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther (1997) 283(2):757-69.
7. Hendricks JC, Kirk D, Panckeri K, Miller MS, Pack AI. Modafinil maintains waking in the fruit fly Drosophila melanogaster. Sleep (2003) 26(2):139-46.
8. Kim D. Practical use and risk of modafinil, a novel waking drug. Environ Health Toxicol (2012) 27:e2012007. doi:10.5620/eht.2012.27.e2012007.
9. Giros B, Wang YM, Suter S, McLeskey SB, PiflC, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem (1994) 269(23):15985-8.
10. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep (1994) 17(5):436-7.
11. Schmitt KC, Reith ME. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS ONE (2011) 6(10):e25790. doi:10.1371/journal.pone.0025790.
12. Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, et al. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry (2012) 72(5):405-13. doi:10.1016/j.biopsych.2012.03.022.
13. Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online (1998) 1(1):49-61.
14. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 329(2):738-46. doi:10.1124/jpet.108.146142.
15. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther (2006) 319(2):561-9. doi:10.1124/jpet.106.106583.
16. Volkow ND, Fowler JS, Logan J, AlexoffD, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA (2009) 301(11):1148-54. doi:10.1001/jama.2009.351.
17. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci (2001) 21(5):1787-94.
18. Cao J, Prisinzano TE, Okunola OM, Kopajtic T, Shook M, Katz JL, et al. Structure-activity relationships at the monoamine transporters for a novel series of modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) analogues. ACS Med Chem Lett (2010) 2(1):48-52. doi:10.1021/ml1002025.
19. Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, et al. Modafinil: a double-blind multicentric study. Sleep (1994) 17(8 Suppl):S107-12.
20. Fujiki N, Cheng T, Yoshino F, Nishino S. Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice. Exp Neurol (2009) 217(1):46-54. doi:10.1016/j.expneurol.2009.01.015.
21. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep (1995) 18(10):817-26.
22. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) (1993) 113(1):76-82. doi:10.1007/BF02244337.
23. Uguen M, Perrin D, Belliard S, Ligneau X, Beardsley PM, Lecomte JM, et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H(3) receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol (2013) 169:632-44. doi:10.1111/bph.12149.
24. Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci (2008) 28(34):8462-9. doi:10.1523/JNEUROSCI.1819-08.2008.
25. Seeman P, Guan HC, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse (2009) 63:698-704. doi:10.1002/syn.20647.
26. Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol (1990) 180(1):49-58. doi:10.1016/0014-2999(90)90591-S.
27. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res (1992) 591(2):319-26. doi:10.1016/0006-8993(92)91713-O.
28. Zhang WP, Ouyang M, Thomas SA. Potency of catecholamines and other L-tyrosine derivatives at the cloned mouse adrenergic receptors. Neuropharmacology (2004) 47(3):438-49. doi:10.1016/j.neuropharm.2004.04.017.
29. De Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport (2001) 12(16):3533-7. doi:10.1097/00001756-200111160-00032.
30. Pan WH, Yang SY, Lin SK. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. Synapse (2004) 53(1):44-52. doi:10.1002/syn.20034.
31. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett (1998) 253(2):135-8. doi:10.1016/S0304-3940(98)00629-6.
32. Tanganelli S, Ferraro L, Bianchi C, Fuxe K. 6-Hydroxy-dopamine treatment counteracts the reduction of cortical GABA release produced by the vigilance promoting drug modafinil in the awake freely moving guinea-pig. Neurosci Lett (1994) 171(1-2):201-4. doi:10.1016/0304-3940(94)90639-4.
33. Tanganelli S, Fuxe K, Ferraro L, Janson AM, Bianchi C. Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol (1992) 345(4):461-5. doi:10.1007/BF00176625.
34. Abekawa T, Ohmori T, Ito K, Koyama T. D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex. Brain Res (2000) 867(1-2):250-4. doi:10.1016/S0006-8993(00)02298-8.
35. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport (1997) 8(13):2883-7. doi:10.1097/00001756-199709080-00016.
36. Exposito I, Sanz B, Porras A, Mora F. Effects of apomorphine and L-methionine sulphoximine on the release of excitatory amino acid neurotransmitters and glutamine in the striatum of the conscious rat. Eur J Neurosci (1994) 6(2):287-91. doi:10.1111/j.1460-9568.1994.tb00271.x.
37. Porras A, Mora F. Dopamine-glutamate-GABA interactions and ageing: studies in the striatum of the conscious rat. Eur J Neurosci (1995) 7(11):2183-8. doi:10.1111/j.1460-9568.1995.tb00640.x.
38. David HN, Ansseau M, Abraini JH. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res Brain Res Rev (2005) 50(2):336-60. doi:10.1016/j.brainresrev.2005.09.002.
39. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J Neurochem (2004) 89(4):834-43. doi:10.1111/j.1471-4159.2004.02355.x.
40. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology (2008) 33(7):1477-502. doi:10.1038/sj.npp.1301534.
41. Wisor JP, O'Hara BF, Terao A, Selby CP, KilduffTS, Sancar A, et al. A role for cryptochromes in sleep regulation. BMC Neurosci (2002) 3:20. doi:10.1186/1471-2202-3-20.
42. Drapeau C, Carrier J. Fluctuation of waking electroencephalogram and subjective alertness during a 25-hour sleep-deprivation episode in young and middle-aged subjects. Sleep (2004) 27(1):55-60.
43. Spiegel K, Leproult R, Van CE. Impact of sleep debt on metabolic and endocrine function. Lancet (1999) 354(9188):1435-9. doi:10.1016/S0140-6736(99)01376-8.
44. Borbély AA, Achermann P. Sleep homeostasis and models of sleep regulation. 3rd ed. In: Kryger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine. Philadelphia: Saunders (2000). p. 377-90.
45. Wisor JP, Dement WC, Aimone L, Williams M, Bozyczko-Coyne D. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav (2006) 85(3):492-9. doi:10.1016/j.pbb.2006.09.018.
46. Kopp C, Petit JM, Magistretti P, Borbely AA, Tobler I. Comparison of the effects of modafinil and sleep deprivation on sleep and cortical EEG spectra in mice. Neuropharmacology (2002) 43(1):110-8. doi:10.1016/S0028-3908(02)00070-9.
47. Bodenmann S, HohoffC, Freitag C, Deckert J, Retey JV, Bachmann V, et al. Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation. Br J Pharmacol (2012) 165(6):1904-13. doi:10.1111/j.1476-5381.2011.01689.x.
48. Bodenmann S, Xu S, Luhmann UF, Arand M, Berger W, Jung HH, et al. Pharmacogenetics of modafinil after sleep loss: catechol-O-methyltransferase genotype modulates waking functions but not recovery sleep. Clin Pharmacol Ther (2009) 85(3):296-304. doi:10.1038/clpt.2008.222.
49. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse (2001) 39(1):32-41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.
50. Cirelli C, Huber R, Gopalakrishnan A, Southard TL, Tononi G. Locus ceruleus control of slow-wave homeostasis. J Neurosci (2005) 25(18):4503-11. doi:10.1523/JNEUROSCI.4845-04.2005.
51. Imeri L, Opp MR. How (and why) the immune system makes us sleep. Nat Rev Neurosci (2009) 10(3):199-210. doi:10.1038/nrn2576.
52. Jouvet M, Bobillier P, Pujol JF, Renault J. Permanent insomnia and diminution of cerebral serotonin due to lesion of the raphe system in cats. J Physiol Paris (1967) 59(1 Suppl):248.
53. Morrow JD, Vikraman S, Imeri L, Opp MR. Effects of serotonergic activation by 5-hydroxytryptophan on sleep and body temperature of C57BL/6J and interleukin-6-deficient mice are dose and time related. Sleep (2008) 31(1):21-33.
54. Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B. Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav (2010) 95(4):449-56. doi:10.1016/j.pbb.2010.03.006.
55. Shuman T, Cai DJ, Sage JR, Anagnostaras SG. Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction. Behav Brain Res (2012) 235(2):105-12. doi:10.1016/j.bbr.2012.07.039.
56. Webb IC, Pollock MS, Mistlberger RE. Modafinil [2-[(diphenylmethyl) sulfinyl]acetamide] and circadian rhythms in syrian hamsters: assessment of the chronobiotic potential of a novel alerting compound. J Pharmacol Exp Ther (2006) 317:882-9. doi:10.1124/jpet.105.099010.
57. Simon P, Hemet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol (1995) 5(4):509-14. doi:10.1016/0924-977X(95)80011-P.
58. Chang ST, Tung CS, Lin YL, Chuang CH, Lee AR, Liu YP. Behavioral and cross sensitization after repeated exposure to modafinil and apomorphine in rats. Chin J Physiol (2010) 53:318-27. doi:10.4077/CJP.2010.AMK067.
59. da Costa CS, Moreira KD, Abrahao KP, Quadros IM, Oliveira MG. Individual differences are critical in determining modafinil-induced behavioral sensitization and cross-sensitization with methamphetamine in mice. Behav Brain Res (2012) 233:367-74. doi:10.1016/j.bbr.2012.05.023.
60. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol (2000) 14(1):53-60. doi:10.1177/026988110001400107.
61. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance-a review of abuse liability issues. Ann Clin Psychiatry (2004) 16(2):101-9. doi:10.1080/10401230490453743.
62. Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol (2007) 568(1-3):112-23. doi:10.1016/j.ejphar.2007.03.044.
63. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) (1996) 126(4):286-92. doi:10.1007/BF02247379.
64. Newman JL, Negus SS, Lozama A, Prisinzano TE, Mello NK. Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol (2010) 18(5):395-408. doi:10.1037/a0021042.
65. Heal DJ, Buckley NW, Gosden J, Slater N, France CP, Hackett D. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil. Neuropharmacology (2013) 73C:348-58. doi:10.1016/j.neuropharm.2013.05.021.
66. Nguyen TL, Tian YH, You IJ, Lee SY, Jang CG. Modafinil-induced conditioned place preference via dopaminergic system in mice. Synapse (2011) 65(8):733-41. doi:10.1002/syn.20892.
67. Quisenberry AJ, Prisinzano TE, Baker LE. Modafinil alone and in combination with low dose amphetamine does not establish conditioned place preference in male Sprague-Dawley rats. Exp Clin Psychopharmacol (2013) 21:252-8. doi:10.1037/a0031832.
68. Mahler SV, Hensley-Simon M, Tahsili-Fahadan P, Lalumiere RT, Thomas C, Fallon RV, et al. Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. Addict Biol (2013). doi:10.1111/j.1369-1600.2012.00506.x.
69. Holtz NA, Lozama A, Prisinzano TE, Carroll ME. Reinstatement of methamphetamine seeking in male and female rats treated with modafinil and allopregnanolone. Drug Alcohol Depend (2012) 120(1-3):233-7. doi:10.1016/j.drugalcdep.2011.07.010.
70. Reichel CM, See RE. Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. Psychopharmacology (Berl) (2010) 210(3):337-46. doi:10.1007/s00213-010-1828-5.
71. Reichel CM, See RE. Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats. Int J Neuropsychopharmacol (2012) 15(7):919-29. doi:10.1017/S1461145711000988.
72. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol (2002) 13(2):105-15. doi:10.1097/00008877-200203000-00002.
73. Rush CR, Kelly TH, Hays LR, Wooten AF. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend (2002) 67(3):311-22. doi:10.1016/S0376-8716(02)00082-0.
74. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology (2008) 33(4):761-8. doi:10.1038/sj.npp.1301472.
75. Malcolm R, Swayngim K, Donovan JL, DeVane CL, Elkashef A, Chiang N, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse (2006) 32(4):577-87. doi:10.1080/00952990600920425.
76. Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend (2009) 104:133-9. doi:10.1016/j.drugalcdep.2009.04.015.
77. Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend (2012) 120(1-3):135-41. doi:10.1016/j.drugalcdep.2011.07.007.
78. Shearer J, Darke S, Rodgers C, Slade T, van BI, Lewis J, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction (2009) 104(2):224-33. doi:10.1111/j.1360-0443.2008.02437.x.
79. Dackis CA, Kampman KM, Lynch KG, Plebani JG, Pettinati HM, Sparkman T, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat (2012) 43(3):303-12. doi:10.1016/j.jsat.2011.12.014.
80. Kozikowski AP, Zhao L, Zhang A, Wang CZ, Flippen-Anderson J, Johnson KM. Structural remodeling of cocaine: design and synthesis of trisubstituted cyclopropanes as selective serotonin reuptake inhibitors. ChemMedChem (2006) 1(1):58-65. doi:10.1002/cmdc.200500016.
81. Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther (2001) 296(3):762-7.
82. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A (1998) 95:7699-704. doi:10.1073/pnas.95.13.7699.
83. Hall FS, Li XF, Sora I, Xu F, Caron M, Lesch KP, et al. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience (2002) 115(1):153-61. doi:10.1016/S0306-4522(02)00379-2.
84. Tilley MR, Cagniard B, Zhuang X, Han DD, Tiao N, Gu HH. Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression. BMC Neurosci (2007) 8:42. doi:10.1186/1471-2202-8-42.
85. Thomsen M, Han DD, Gu HH, Caine SB. Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. J Pharmacol Exp Ther (2009) 331:204-11. doi:10.1124/jpet.109.156265.
86. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, et al. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci U S A (2006) 103:9333-8. doi:10.1073/pnas.0600905103.
87. Schmitt K, Rothman RB, Reith M. Non-classical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators and partial substrates. J Pharmacol Exp Ther (2013) 346(1):2-10. doi:10.1124/jpet.111.191056.
88. Beuming T, KniazeffJ, Bergmann ML, Shi L, Gracia L, Raniszewska K, et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci (2008) 11(7):780-9. doi:10.1038/nn.2146.
89. Xie Z, Miller GM. A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J Pharmacol Exp Ther (2009) 330(1):316-25. doi:10.1124/jpet.109.153775.
90. Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry (2013) 18(5):543-56. doi:10.1038/mp.2012.57.
91. Xie Z, Miller GM. Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther (2007) 321(1):128-36. doi:10.1124/jpet.106.117382.
92. Szabo ST, Machado-Vieira R, Yuan P, Wang Y, Wei Y, Falke C, et al. Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology (2009) 56(1):47-55. doi:10.1016/j.neuropharm.2008.08.015.
93. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol (1998) 38(3):276-82. doi:10.1002/j.1552-4604.1998.tb04395.x.
94. Darwish M, Kirby M, Hellriegel ET, Yang R, Robertson P. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig (2009) 29:87-100. doi:10.2165/0044011-200929020-00003.
95. Lukas SE, Sholar M, Kouri E, Fukuzako H, Mendelson JH. Marijuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacol Biochem Behav (1994) 48(3):715-21. doi:10.1016/0091-3057(94)90338-7.
96. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol (2002) 26(7):382-92. doi:10.1093/jat/26.7.382.
97. Kimmel HL, Negus SS, Wilcox KM, Ewing SB, Stehouwer J, Goodman MM, et al. Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav (2008) 90(3):453-62. doi:10.1016/j.pbb.2008.03.032.
98. Wee S, Carroll FI, Woolverton WL. A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology (2006) 31(2):351-62. doi:10.1038/sj.npp.1300795.
99. Woolverton WL, Wang Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol (2004) 486(3):251-7. doi:10.1016/j.ejphar.2004.01.003.
100. Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, et al. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol (2004) 143(5):649-61. doi:10.1038/sj.bjp.0705964.
101. Dietrich H, Jenck F. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berl) (2010) 212(2):145-54. doi:10.1007/s00213-010-1933-5.
102. Blanco-Centurion C, Liu M, Konadhode R, Pelluru D, Shiromani PJ. Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice. Sleep (2013) 36(1):31-40. doi:10.5665/sleep.2296.
103. Liu M, Blanco-Centurion C, Konadhode R, Begum S, Pelluru D, Gerashchenko D, et al. Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci (2011) 31(16):6028-40. doi:10.1523/JNEUROSCI.6069-10.2011.
104. Cohen DA, Freitas C, Tormos JM, Oberman L, Eldaief M, Pascual-Leone A. Enhancing plasticity through repeated rTMS sessions: the benefits of a night of sleep. Clin Neurophysiol (2010) 121(12):2159-64. doi:10.1016/j.clinph.2010.05.019.
105. Marshall L, Helgadottir H, Molle M, Born J. Boosting slow oscillations during sleep potentiates memory. Nature (2006) 444(7119):610-3. doi:10.1038/nature05278.